KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to -$399.1 million.

  • Vertex Pharmaceuticals' Change in Accured Expenses fell 2467.98% to -$399.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $148.5 million, marking a year-over-year decrease of 3024.89%. This contributed to the annual value of $148.5 million for FY2025, which is 3024.89% down from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Change in Accured Expenses is -$399.1 million, which was down 2467.98% from $332.9 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $485.5 million during Q2 2022, with a 5-year trough of -$437.8 million in Q4 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' median Change in Accured Expenses value was $149.8 million (recorded in 2021), while the average stood at $81.9 million.
  • The largest annual percentage gain for Vertex Pharmaceuticals' Change in Accured Expenses in the last 5 years was 116703.3% (2022), contrasted with its biggest fall of 95507.81% (2022).
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Change in Accured Expenses stood at $51.2 million in 2021, then tumbled by 955.08% to -$437.8 million in 2022, then increased by 18.52% to -$356.7 million in 2023, then increased by 10.26% to -$320.1 million in 2024, then fell by 24.68% to -$399.1 million in 2025.
  • Its Change in Accured Expenses was -$399.1 million in Q4 2025, compared to $332.9 million in Q3 2025 and $166.6 million in Q2 2025.